• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    5/31/22 8:19:27 AM ET
    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Hospital/Nursing Management
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATIP alert in real time by email

     

    Gainers

    • TherapeuticsMD (NASDAQ:TXMD) stock rose 340.6% to $9.43 during Tuesday's pre-market session. The company's market cap stands at $81.7 million.
    • Endo International (NASDAQ:ENDP) stock increased by 12.76% to $0.53. The market value of their outstanding shares is at $124.6 million.
    • Atreca (NASDAQ:BCEL) shares moved upwards by 10.71% to $1.86. The market value of their outstanding shares is at $71.7 million.
    • Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 10.64% to $3.95. The market value of their outstanding shares is at $54.3 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 8.99% to $0.47. The company's market cap stands at $12.5 million.
    • First Wave BioPharma (NASDAQ:FWBI) stock increased by 8.57% to $0.4. The market value of their outstanding shares is at $8.6 million.

    Losers

    • Genocea Biosciences (NASDAQ:GNCA) shares decreased by 22.6% to $0.05 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.8 million.
    • Soligenix (NASDAQ:SNGX) shares fell 16.12% to $0.5. The company's market cap stands at $21.6 million.
    • Eton Pharmaceuticals (NASDAQ:ETON) stock declined by 14.52% to $2.71. The company's market cap stands at $68.3 million.
    • TG Therapeutics (NASDAQ:TGTX) shares fell 13.89% to $4.45. The company's market cap stands at $643.0 million.
    • ATI Physical Therapy (NYSE:ATIP) shares fell 9.75% to $1.76. The company's market cap stands at $364.0 million.
    • SIGA Technologies (NASDAQ:SIGA) stock fell 9.22% to $12.42. The market value of their outstanding shares is at $899.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATIP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATIP
    $BCEL
    $ELDN
    $ENDP

    CompanyDatePrice TargetRatingAnalyst
    TG Therapeutics Inc.
    $TGTX
    10/6/2025$60.00Buy
    H.C. Wainwright
    TG Therapeutics Inc.
    $TGTX
    7/10/2025$37.00Neutral
    Goldman
    Eledon Pharmaceuticals Inc.
    $ELDN
    6/18/2025$9.00Buy
    H.C. Wainwright
    Eledon Pharmaceuticals Inc.
    $ELDN
    1/28/2025$9.00Buy
    Guggenheim
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    TG Therapeutics Inc.
    $TGTX
    10/29/2024$50.00Buy
    TD Cowen
    More analyst ratings

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)

    4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

    12/29/25 4:23:31 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J bought $20,000 worth of shares (15,132 units at $1.32), increasing direct ownership by 3,993% to 15,511 units (SEC Form 4)

    4 - SOLIGENIX, INC. (0000812796) (Issuer)

    10/3/25 1:18:09 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Opaleye Management Inc. bought $125,484 worth of shares (7,930 units at $15.82) (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    6/12/25 4:32:51 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on TG Therapeutics with a new price target

    H.C. Wainwright resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $60.00

    10/6/25 8:31:23 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on TG Therapeutics with a new price target

    Goldman resumed coverage of TG Therapeutics with a rating of Neutral and set a new price target of $37.00

    7/10/25 9:01:31 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Eledon Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    6/18/25 7:57:38 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Riedel Norbert G exercised 30,000 in-the-money shares at a strike of $4.42, increasing direct ownership by 600% to 35,000 units (SEC Form 4)

    4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

    2/5/26 5:18:48 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Charney Laurence N gifted 43,197 shares, decreasing direct ownership by 19% to 179,690 units (SEC Form 4)

    4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

    1/29/26 5:24:42 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nguyen Diem converted options into 55,902 shares and covered exercise/tax liability with 22,804 shares, increasing direct ownership by 49% to 100,751 units (SEC Form 4)

    4 - SIGA TECHNOLOGIES INC (0001010086) (Issuer)

    1/28/26 4:05:10 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    SEC Filings

    View All

    SEC Form 10-K filed by SIGA Technologies Inc.

    10-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    3/10/26 4:50:46 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SIGA TECHNOLOGIES INC (0001010086) (Filer)

    3/10/26 4:05:48 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Eton Pharmaceuticals Inc.

    S-8 - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    3/6/26 4:05:54 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

    10/31/24 4:38:40 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

    Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

    12/28/22 12:54:09 PM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

    Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

    12/29/21 7:23:57 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

    Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026  Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. "In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income," stated Diem

    3/10/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

    PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Behçet's Disease. The PIM designation is the first step and a prerequisite towards inclusion in the UK Early

    3/10/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

    IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). "Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcin

    3/10/26 7:00:00 AM ET
    $ELDN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Leadership Updates

    Live Leadership Updates

    View All

    Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

    Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F

    9/23/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA Appoints Retired General John M. Keane to its Board of Directors

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John "Jack" Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice Chief of Staff of the U.S. Army from 1999 to 2003. He is a foreign policy and national security expert who serves as an advisor to presidents, cabinet officials, members of congress, international leaders, CEOs, and business leaders. He also provide

    3/18/25 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

    Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical

    12/3/24 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Financials

    Live finance-specific insights

    View All

    SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update

    Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026  Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. "In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income," stated Diem

    3/10/26 4:01:00 PM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

    DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast:                   Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email

    3/3/26 4:30:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results

    NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 10, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-17

    3/3/26 7:30:00 AM ET
    $SIGA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATIP
    $BCEL
    $ELDN
    $ENDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care